Recent Finacing
Recent Raise
BioAge develops obesity and metabolic-disease therapies using a human longevity data discovery platform; oral apelin receptor agonist azelaprag is entering Phase 2 with tirzepatide, plus preclinical aging programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at BioAge.
